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Editorial on the Research Topic
Function of Renal Sympathetic Nerves
INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity worldwide. The
incidence of CVD is increasing in association with the growing prevalence of hypertension,
diabetes, and obesity. This is occurring despite established effective therapies for hypertension.
Thus, new methods for risk reduction are still needed (Cutler et al., 2008). The aim of this research
topic was to evaluate the efficacy and safety of renal denervation (RDN), to explore the contribution
of both afferent and efferent renal nerve activity to hypertension and non-hypertension disorders,
and to stimulate future research to better understand the function of the renal nerves and the effects
of RDN by highlighting gaps in knowledge.
EVALUATION OF CATHETER-BASED RENAL DENERVATION FOR
THE TREATMENT OF HYPERTENSION
Strong evidence that sympathetic overactivity is associated with the development of hypertension,
combined with the demonstration that RDN prevents or delays hypertension in a variety of animal
models, laid the groundwork for the introduction of RDN as a clinical therapy in humans (DiBona
and Esler, 2010). In 2007, a novel, minimally invasive RDN ablation catheter was first trialed in
hypertensive patients, with a 93% success rate of lowering blood pressure (BP) for at least 3 years
post-RDN (Krum et al., 2014). These studies were met with acclaim (Lakhanpal and Domanski,
2012). However, a large scale, sham-controlled clinical trial (Symplicity HTN-3) failed to show
reductions in BP greater than sham (Bhatt et al., 2014). It is now clear that poor trial design
contributed to this outcome; only 19 of the 340 patients received at least the recommended 4+
ablations per artery and in these patients the falls in BP were greatest (Kandzari et al., 2015). In
addition, the report by the Global SYMPLICITY Registry of 1,000 consecutively enrolled patients
not only confirmed the safety of RDN but also suggested that RDN lowers office and ambulatory
BP at 6 months post-procedure (Bohm et al., 2015). In the current volume, Fadl Elmula et al.
summarizes the results of recent clinical RDN trials and rightly raised concerns regarding the
interpretation of this data and called for caution in the implementation of this procedure. The
authors point out that these trials did not confirm the marked BP lowering effect observed by
initial RDN studies (Krum et al., 2009; Esler et al., 2010). In addition, they suggested that the
BP lowering effect of RDN may be limited to discrete patient populations, and that it would be
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worthwhile searching for potential predictors of true responders
to RDN. Briasoulis and Bakris reviewed the role of renal
sympathetic nerves in hypertension and clinical applications
of RDN in resistant hypertension. In light of the results from
the Symplicity HTN-3 trial, the authors suggested that future
randomized trials should be performed in experienced centers,
using newer catheters, and in carefully selected compliant
patients with true resistant hypertension.
EFFECTS OF RENAL DENERVATION
BEYOND BLOOD PRESSURE CONTROL
It is noteworthy that RDN has also been shown to be effective
in the treatment of other conditions coexisting with resistant
hypertension. Thorp and Schlaich contributed a comprehensive
review on RDN for hypertension and beyond. The non-
hypertensive disorders that may also be affected by RDN include
chronic kidney disease, chronic heart failure, left ventricular
hypertrophy, arrhythmias, and metabolic diseases. Evidence
suggests that clinical benefits beyond BP reduction could be
gained following RDN in patients with these disorders. However,
randomized controlled trials are needed before the application
of RDN becomes routine in clinical practice for these patient
cohorts. Moreover, these intriguing findings suggest that there
is still a lot we don’t understand about the function of the renal
nerves.
Heart Failure
The kidney has a rich afferent sensory and efferent sympathetic
innervation. It is now apparent that afferent renal nerve activity
can reflexly modulate sympathetic outflow, not just to the kidney,
but also to other organs, which may be one mechanism whereby
RDNmight improve outcomes in heart failure. Ramchandra and
Barrett reviewed the mechanisms that contribute to enhanced
renal sympathetic nerve activity (SNA) during heart failure,
with an emphasis on afferent reflexes and central mechanisms.
Booth et al. also contributed a review on this topic, focusing
on critically assessing recent preclinical and clinical evidence
supporting RDN as a potential treatment for heart failure. It was
concluded that a reflex reduction in cardiac SNA in heart failure
may be one beneficial effect of RDN. Booth et al. also explored
the effect of RDN on the renal afferents, and provided evidence
for both the destruction and then significant regrowth of afferent
renal nerves. However, what effect ablating the afferent nerves
play in mediating the responses to RDN is still largely unknown.
Finally, Schiller et al. (2015) reviewed the contribution of renal
nerves to the pathogenesis of chronic heart failure, providing an
overview of clinical RDN studies to date. This culminated in a call
for more research to determine how RDN may be employed as a
safe and effective treatment in chronic heart failure.
Kidney Disease
Strong evidence demonstrates that renal SNA is elevated in both
acute and chronic kidney disease. Although less robust, evidence
also implicates increased afferent sensory nerve activity in kidney
disease. In a primary study, Salman et al. demonstrated using
telemetry-based recordings in rats with chronic kidney disease
(Lewis Polycystic Kidney rats) that renal SNA directly correlated
with BP. This study confirmed the notion that elevated renal
SNA is likely a key contributor to hypertensive kidney disease.
In an acute study, Goulding et al. examined the contribution
of the renal nerves to baroreflex control of renal SNA and
excretory function in cisplatin-induced renal failure in rats. The
authors found that impaired renal function was associated with
blunting of baroreflex gain and increased renal SNA, and that
RDN restored these abnormalities. The results of this study
suggested that dysregulation of renal SNA plays an important
role in renal failure and that RDN may provide benefits for
patients with kidney disease. In combination, this evidence led
to the suggestion that kidney disease may also be amenable to
RDN and Sanders and Blankestijn contributed a review of the
clinical evidence arguing that RDN may have a place in the
management of chronic kidney disease. RDN has been trialed in
models of chronic kidney disease and been shown to be effective
in lowering BP, though concerns were raised regarding the ability
to adequately mount a response to hemorrhage (Singh et al.,
2017).
LONG-TERM SAFETY CONCERNS
FOLLOWING RDN
The introduction of catheter-based RDN initially moved forward
at a rapid pace and though this has slowed, interest still remains
strong. In part, this reduced momentum stems from concerns
surrounding the lack of understanding of the long-term impact of
RDN.Wang pointed out that although RDN is generally regarded
as a safe procedure, some reports with small sample size have
shown that the incidence of renal artery stenosis after RDN could
be up to 18.2%; though this may depend on operator experience
and the type of catheter employed. However, the safety of RDN
needs to be continuously monitored.
In another study, Wang et al. examined the possible
side effects of RDN in apolipoprotein E-deficient mice with
hypertension induced by angiotensin II infusion. It was found
that RDN increased atherosclerosis in the aortic arch despite
a reduction in systolic BP in the mice. In contrast, RDN
has been reported to decrease atherosclerosis in normotensive
apolipoprotein E-deficient mice fed a high fat diet (Wang et al.,
2015). Therefore, whether RDN promotes atherosclerosis in
patients with resistant hypertension requires investigation in
follow-up studies. In fact, the consequences of RDN in all patient
populations in which this procedure is being trialed requires
longer term follow-up, given evidence that the renal nerves
regrow over time (Booth et al., 2015).
CONCLUSION
Thus, the articles contained in this collection, contribute to our
understanding of the function of the renal nerves, the effects
of RDN as a treatment for hypertension and non-hypertensive
disorders, and the side effects of RDN. However, much remains
to be learned in terms of intra-procedural verification of the
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completeness of RDN, patient selection and long-term safety of
RDN.
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